Application of serum HCV-RNA load and anti-HCV concentration detection in clinical diagnosis of hepatitis C
-
摘要: 目的:探讨血清HCV-RNA载量及抗-HCV浓度检测在丙型肝炎临床诊断中的应用。方法:选取2017-04-2018-04治疗的丙型肝炎患者100例纳入试验组,选取同期30例健康人群纳入对照组。采用荧光定量PCR法对其进行HCV-RNA载量检测,ELISA法检测抗-HCV浓度、全自动生化分析仪检测血清中AST、ALT、TBIL的浓度,并进行统计学分析。结果:100例标本中抗-HCV阳性者89例,阳性率为89%;随着HCV-RNA载量的不断增加,抗-HCV阳性率不断升高,差异有统计学意义(P<0.05);试验组的抗-HCV s/co值高于对照组,差异有统计学意义(P<0.05);试验组的血清AST、ALT、TBIL值均明显高于对照组,差异有统计学意义(P<0.05)。结论:HCV-RNA载量联合抗-HCV及肝功能指标检测,不仅可有效对患者的感染、病情严重程度做出准确判断,还可以对临床治疗进行监测。Abstract: Objective:To investigate the application of serum HCV-RNA load and anti-HCV concentration detection in the clinical diagnosis of hepatitis C.Method:A total of 100 patients with hepatitis C treated with 2017-04-2018-04 were enrolled in the experimental group.Thirty healthy people in the same period were selected as the control group.The HCV-RNA load was detected by real-time PCR,the anti-HCV concentration was detected by ELISA,and the concentrations of AST,ALT and TBIL in serum were detected by automatic biochemical analyzer,and statistical analysis was performed.Result:Of the 100 specimens,89 were positive for anti-HCV,and the positive rate was 89%.With the increase of HCV-RNA load,the positive rate of anti-HCV increased continuously,the difference was statistically significant(P<0.05).The anti-HCV s/co value of the experimental group was higher than that of the control group,and the difference was statistically significant(P<0.05).The serum AST,ALT and TBIL values of the experimental group were significantly higher than the control group,and the difference was statistically significant(P<0.05).Conclusion:HCV-RNA load combined with anti-HCV and liver function indicators can not only effectively determine the patient's infection and severity,but also monitor clinical treatment.
-
Key words:
- hepatitis C /
- HCV-RNA load /
- anti-HCV concentration /
- detection
-
-
[1] 徐楚,张平安.慢性丙型肝炎病毒感染与模式识别受体的研究进展[J].职业与健康,2018,34(7):1000-1004,封3页.
[2] 李媛,黄古叶,莫春梅,等.慢性丙型肝炎中医证候分布规律的研究[J].中西医结合肝病杂志,2018,28(1):11-13.
[3] 路遥,郝红晓,申戈,等.慢性丙型肝炎干扰素强化治疗失败患者的PR联合DAA再治疗研究[J].中华实验和临床病毒学杂志,2018,32(1):66-69.
[4] 纪东,游邵丽,辛邵杰.丙型肝炎防治指南(2015更新版)要点解读[J].传染病信息,2016,29(1):20-23.
[5] 魏来.达诺瑞韦及其联合PR方案治疗慢性丙型肝炎研究进展[J].中华临床感染病杂志,2018,11(2):84-89.
[6] 王琴,饶慧瑛,于宁,等.成人慢性丙型肝炎合并疾病及用药现状分析[J].中华肝病杂志,2018,26(3):225-232.
[7] 杨甲,饶慧瑛.抗病毒治疗对慢性丙型肝炎肝纤维化和肝硬化的影响[J].中华肝脏病杂志,2018,26(3):175-178.
[8] 何雅婧,刘智泓,侯金林.直接抗病毒药物治疗慢性丙型肝炎的方案选择[J].中华肝脏病杂志,2018,26(3):169-172.
[9] 王琛琛,郭晓静,王皓,等.洛阳市某三甲医院丙型肝炎病毒基因分型研究[J].中华传染病杂志,2018,36(1):45-46.
[10] 张民,王德欣,郭璐.慢性丙型肝炎患者生命质量及其影响因素分析[J].中国现代医学杂志,2018,28(14):112-116.
-
计量
- 文章访问数: 362
- PDF下载数: 1049
- 施引文献: 0